ATE411012T1 - Behandlung der lipodystrophie mit renin- angiotensin system inhibitoren - Google Patents

Behandlung der lipodystrophie mit renin- angiotensin system inhibitoren

Info

Publication number
ATE411012T1
ATE411012T1 AT02749123T AT02749123T ATE411012T1 AT E411012 T1 ATE411012 T1 AT E411012T1 AT 02749123 T AT02749123 T AT 02749123T AT 02749123 T AT02749123 T AT 02749123T AT E411012 T1 ATE411012 T1 AT E411012T1
Authority
AT
Austria
Prior art keywords
lipodystrophy
renin
treatment
angiotensin system
system inhibitors
Prior art date
Application number
AT02749123T
Other languages
English (en)
Inventor
John Francis Martin
Jorge D Erusalimsky
Hugh Edward Montgomery
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of ATE411012T1 publication Critical patent/ATE411012T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02749123T 2001-08-09 2002-08-07 Behandlung der lipodystrophie mit renin- angiotensin system inhibitoren ATE411012T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119460.4A GB0119460D0 (en) 2001-08-09 2001-08-09 The use of inhibitors of the renin-angiotensin system

Publications (1)

Publication Number Publication Date
ATE411012T1 true ATE411012T1 (de) 2008-10-15

Family

ID=9920113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02749123T ATE411012T1 (de) 2001-08-09 2002-08-07 Behandlung der lipodystrophie mit renin- angiotensin system inhibitoren

Country Status (19)

Country Link
US (1) US7022693B2 (de)
EP (1) EP1414421B1 (de)
JP (1) JP2005527462A (de)
KR (1) KR20040054665A (de)
CN (1) CN1541094A (de)
AP (1) AP1731A (de)
AT (1) ATE411012T1 (de)
AU (1) AU2002319535B2 (de)
CA (1) CA2456549A1 (de)
DE (1) DE60229398D1 (de)
DK (1) DK1414421T3 (de)
ES (1) ES2332884T3 (de)
GB (1) GB0119460D0 (de)
HU (1) HUP0401041A3 (de)
MX (1) MXPA04001174A (de)
NO (1) NO20040561L (de)
PL (1) PL367941A1 (de)
WO (1) WO2003013486A1 (de)
ZA (1) ZA200400887B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635263A3 (de) * 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin (AII)-antagonisten als Inhibitoren des Wachstums von Fettgewebe.
KR100523112B1 (ko) 1997-10-17 2005-10-19 유로진 리미티드 레닌-안지오텐신계 억제제의 사용
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
CN1541094A (zh) 2004-10-27
AP2004002980A0 (en) 2004-03-31
WO2003013486A1 (en) 2003-02-20
US7022693B2 (en) 2006-04-04
GB0119460D0 (en) 2001-10-03
EP1414421B1 (de) 2008-10-15
JP2005527462A (ja) 2005-09-15
DK1414421T3 (da) 2008-12-08
ES2332884T3 (es) 2010-02-15
MXPA04001174A (es) 2005-02-17
NO20040561L (no) 2004-03-23
US20040209941A1 (en) 2004-10-21
EP1414421A1 (de) 2004-05-06
DE60229398D1 (de) 2008-11-27
HUP0401041A3 (en) 2004-10-28
CA2456549A1 (en) 2003-02-20
AP1731A (en) 2007-03-30
ZA200400887B (en) 2005-02-03
KR20040054665A (ko) 2004-06-25
PL367941A1 (en) 2005-03-07
AU2002319535B2 (en) 2005-01-06
HUP0401041A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20033017L (no) Substituerte difenylheterosykluser til behandling av HCV-infeksjon
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
DE60118179D1 (de) Behandlung von zirkulierenden wassersystemen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
ATE417616T1 (de) Behandlung von mukositis
EP1117431A4 (de) Behandlung von acidose
DE60211913D1 (de) Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
NO20024777L (no) Kinolinyl-piperidin-4-yliden-metyl-benzamid derivater til behandling av smerte
DE60103685D1 (de) Behandlung von Poriomania
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60026821D1 (de) Behandlung von bohrspülung
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
ATE411012T1 (de) Behandlung der lipodystrophie mit renin- angiotensin system inhibitoren
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
DE60317661D1 (de) Annelierte pyrrol-verbindungen als protonenpumpenhemmer zur behandlung von geschwüren
DE50105650D1 (de) Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties